Search
Ravulizumab
go.drugbank.com/drugs/DB11580ApprovedInvestigational[L39690] Ravulizumab was engineered from [eculizumab], another complement inhibitor, to increase the duration of action and reduce the frequency of drug administration. … [A244465] It was later approved by the European Commission on July 2, 2019, for the same indications.[L39710] Ravulizumab is also used to treat myasthenia gravis.
Dulaglutide
go.drugbank.com/drugs/DB09045ApprovedInvestigationaltherapy to diet and exercise in the management of 2 diabetes (T2DM). … It is the first T2DM drug approved to reduce major adverse cardiovascular events (MACE) risk in primary and secondary prevention populations.[L34665]
Ferric pyrophosphate citrate
go.drugbank.com/drugs/DB13995ApprovedThe ferric ion is strongly complexed by pyrophosphate and citrate.[A31979] FPC is categorized in Japan as a second class OTC drug. … Free iron presents several side effects as it can catalyze free radical formation and lipid peroxidation as well as the presence of interactions of iron in plasma.
Baxdrostat
go.drugbank.com/drugs/DB19090ApprovedInvestigationalBaxdrostat offers an upstream alternative to traditional mineralocorticoid receptor antagonists (MRAs), such as [spironolactone], which often induce off-target endocrine side effects like gynecomastia … due to non-selective steroidal activities [A275513, A275514].
Enfortumab vedotin
go.drugbank.com/drugs/DB13007ApprovedInvestigational2019 under the brand name Padcev<sup>TM</sup>. … The clinical development of enfortumab vedotin was the result of a collaboration between Astellas Pharma and Seattle Genetics [A188868] and it was first approved for use in the United States in December
Sofosbuvir
go.drugbank.com/drugs/DB08934ApprovedInvestigationalThis is an important advantage relative to HCV drugs that target other viral enzymes such as the protease, for which rapid development of resistance has proven to be an important cause of therapeutic failure … the intent to cure, or achieve a sustained virologic response (SVR), after 12 weeks of daily therapy.
Enzacamene
go.drugbank.com/drugs/DB11219ApprovedWhile its effects on the human reproductive system as an endocrine disruptor are being investigated, its use in over-the-counter and cosmetic products is approved by Health Canada. … It is used in cosmetic products such as sunscreen to provide skin protection against UV rays.
Mixtures: Bain De Soleil Protection Lotion SPF 15Gefapixant
go.drugbank.com/drugs/DB15097Approved[L48596] Gefapixant is a novel antagonist of the P2X3 receptor that works to reduce the cough reflex in patients with chronic cough. … [L48596,L48591] It is the first therapy to be approved for the treatment of RCC or UCC in the EU.[L48601]
Megestrol acetate
go.drugbank.com/drugs/DB00351ApprovedInvestigationalVet approvedA progestational hormone used most commonly as the acetate ester. As the acetate, it is more potent than progesterone both as a progestagen and as an ovulation inhibitor. … It has also been used in the palliative treatment of breast cancer.
Categories: Sex Hormones and Modulators of the Genital SystemFerric derisomaltose
go.drugbank.com/drugs/DB15617ApprovedInvestigationalThe latter is an iron carbohydrate oligosaccharide that works to release iron. Ferric derisomaltose was developed by Pharmacosmos Therapeutics ad was granted FDA approval in January 2020. … [L11581,L11587] Clinical trials show that it is non-inferior to [iron sucrose], another form of iron that is often administered in iron deficiency, and less likely to cause serious hypersensitivity that